West Pharmaceutical Services reported second-quarter organic sales growth of 12.7% and adjusted earnings up 28.8% to $2.37 per share, driven by faster High-Value Product growth and wider margins. HVP Components generated $424.1 million in sales, or 49% of total company revenues, and grew 18.4% organically, supported by biologics, GLP-1 elastomers, and customer upgrades tied to Annex 1 requirements. Management expects Annex 1 and broader HVP conversion to add about 200 basis points to 2026 revenue growth, with just under 800 related projects in hand, up 50% from a year earlier. Second-quarter gross margin expanded 200 basis points year over year to 37.7%, and adjusted operating margin increased 230 basis points to 22.6%, helped by favorable HVP mix, pricing, and operating leverage. The company trades at 37.1 times forward 12-month earnings, versus 18.0 times for its Zacks sub-industry and 20.7 times for the S&P 500, a sizable relative premium though below its five-year median of 39.1 times. West Vantage grew just 0.8% organically in the second quarter due to cyber-related production downtime, and Standard Products grew only 0.7% organically, while the company ended June with $435.8 million in cash and cash equivalents against $202.9 million of total debt and repurchased 1.8 million shares for $454.3 million in the first half of 2026 under its $1 billion authorization.
West Pharmaceutical Services IncStrong Q2 earnings, margin expansion, and buybacks support premium valuation.
Eli Lilly and Company
Novo Nordisk A/S